drugset
drugset / Trial / NCT00375401

A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety

NCT00375401 ↗

Phase 3 Terminated 2536 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults

Timeline

Start
2006-10
Primary completion
2009-01
Completion
2009-01

Outcome

Outcome not reported

Stopped: “See termination reason in detailed description.”

Drugs

EvaluationDrugModalityDoseRoute
Subject OTENABANT Small molecule — —

Indications

obesity disorder